At the conclusion of this activity, participants should be able to:

• Become familiar with new immunotherapies used in the treatment of hematolymphoid neoplasms
• Understand the approaches to minimal residual disease in plasma cell myeloma
• Recognize strategies for optimizing flow cytometric results in the era of immunotherapy